Oncotarget

Research Papers:

miR-31 is distinctively overexpressed in primary male extramammary Paget's disease

Hao Guo _, Rui-Qun Qi, Ya-Ni Lv, He-Xiao Wang, Yu-Xiao Hong, Song Zheng, Jiu-Hong Li, Xing-Hua Gao and Hong-Duo Chen

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:24559-24563. https://doi.org/10.18632/oncotarget.8230

Metrics: PDF 1468 views  |   HTML 1640 views  |   ?  


Abstract

Hao Guo1,*, Rui-Qun Qi1,*, Ya-Ni Lv1, He-Xiao Wang1, Yu-Xiao Hong1, Song Zheng1, Jiu-Hong Li1, Xing-Hua Gao1, Hong-Duo Chen1

1Department of Dermatology, No.1 Hospital of China Medical University, Shenyang, China

*These authors have contributed equally to this work

Correspondence to:

Hong-Duo Chen, e-mail: [email protected]

Xing-Hua Gao, e-mail: [email protected]

Jiu-Hong Li, e-mail: [email protected]

Keywords: miRNA, miR-31, non-melanoma skin cancer, extramammary Paget’s disease, apocrine glands

Received: December 12, 2015    Accepted: February 28, 2016    Published: March 21, 2016

ABSTRACT

MicroRNAs (miRNAs) are small noncoding RNAs involved in cancer development. Extramammary Paget’s disease (EMPD) is a rare cutaneous malignancy and the role of miRNAs in EMPD remains unknown. Here, we used TaqMan miRNA arrays to characterize miRNA expression profile in EMPD and further validated the candidates by single RT-PCR. Total 12 cases EMPD were involved in this study. Using laser capture micro-dissection technique, we collected EMPD tumor cells (ET, n=12), normal epidermal cells (NE, n=12) and normal apocrine glands cells (NA, n=7). MiRNA arrays from two pairs of ET and corresponding NE showed that miR-375, miR-10b, miR-31, miR-31* were differentially expressed. The single real-time PCR (RT-PCR) further confirmed that miR-375, miR-31 and miR-31* were upregulated in EMPD cells than those of the normal epidermis and apocrine glands. Our preliminary study suggested that these miRNAs could be involved in EMPD development and miR-31 may serve as potential biomarkers of EMPD.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8230